Seek Returns logo

CI vs. ILMN: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at CI and ILMN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolCIILMN
Company NameThe Cigna GroupIllumina, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Providers & ServicesLife Sciences Tools & Services
Market Capitalization76.64 billion USD16.01 billion USD
ExchangeNYSENasdaqGS
Listing DateMarch 31, 1982July 28, 2000
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of CI and ILMN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

CI vs. ILMN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolCIILMN
5-Day Price Return5.94%5.87%
13-Week Price Return-9.07%23.95%
26-Week Price Return-0.05%-17.66%
52-Week Price Return-12.50%-18.81%
Month-to-Date Return7.38%-1.56%
Year-to-Date Return3.97%-24.34%
10-Day Avg. Volume2.48M2.25M
3-Month Avg. Volume1.90M2.30M
3-Month Volatility33.87%41.84%
Beta0.471.40

Profitability

Return on Equity (TTM)

CI

12.27%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

CI’s Return on Equity of 12.27% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

ILMN

55.15%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

ILMN’s Return on Equity of 55.15% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

CI vs. ILMN: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

CI

1.92%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

CI’s Net Profit Margin of 1.92% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

ILMN

29.37%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

ILMN’s Net Profit Margin of 29.37% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

CI vs. ILMN: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

CI

3.41%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

CI’s Operating Profit Margin of 3.41% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

ILMN

30.21%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

An Operating Profit Margin of 30.21% places ILMN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

CI vs. ILMN: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolCIILMN
Return on Equity (TTM)12.27%55.15%
Return on Assets (TTM)3.26%20.47%
Net Profit Margin (TTM)1.92%29.37%
Operating Profit Margin (TTM)3.41%30.21%
Gross Profit Margin (TTM)9.86%66.55%

Financial Strength

Current Ratio (MRQ)

CI

0.79

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

CI’s Current Ratio of 0.79 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ILMN

1.81

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

ILMN’s Current Ratio of 1.81 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

CI vs. ILMN: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

CI

0.77

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

CI’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ILMN

0.88

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

ILMN’s leverage is in the upper quartile of the Life Sciences Tools & Services industry, with a Debt-to-Equity Ratio of 0.88. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

CI vs. ILMN: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

CI

2.32

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

ILMN

-2.28

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

ILMN has a negative Interest Coverage Ratio of -2.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

CI vs. ILMN: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolCIILMN
Current Ratio (MRQ)0.791.81
Quick Ratio (MRQ)0.681.28
Debt-to-Equity Ratio (MRQ)0.770.88
Interest Coverage Ratio (TTM)2.32-2.28

Growth

Revenue Growth

CI vs. ILMN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

CI vs. ILMN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

CI

2.11%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

CI’s Dividend Yield of 2.11% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

ILMN

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

ILMN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

CI vs. ILMN: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

CI

31.63%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

CI’s Dividend Payout Ratio of 31.63% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ILMN

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

ILMN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

CI vs. ILMN: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolCIILMN
Dividend Yield (TTM)2.11%0.00%
Dividend Payout Ratio (TTM)31.63%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

CI

15.01

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

CI’s P/E Ratio of 15.01 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ILMN

12.32

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

In the lower quartile for the Life Sciences Tools & Services industry, ILMN’s P/E Ratio of 12.32 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

CI vs. ILMN: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

CI

0.29

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

CI’s P/S Ratio of 0.29 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ILMN

3.62

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

ILMN’s P/S Ratio of 3.62 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

CI vs. ILMN: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

CI

2.20

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

CI’s P/B Ratio of 2.20 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

ILMN

6.69

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

ILMN’s P/B Ratio of 6.69 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

CI vs. ILMN: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolCIILMN
Price-to-Earnings Ratio (TTM)15.0112.32
Price-to-Sales Ratio (TTM)0.293.62
Price-to-Book Ratio (MRQ)2.206.69
Price-to-Free Cash Flow Ratio (TTM)11.6515.04